

Diatherix









Flu *Plus*



Developed by a unique laboratory providing accurate and actionable results in one day for infectious diseases and antibiotic resistance genes utilizing innovative molecular technologies, including proprietary TEM-PCR™



DxRx Linking Diagnostics to Therapeutics™



Eurofins Diatherix Distinctions:

- Delivers one-day results
- Identifies bacteria regardless of recent antibiotic use
- Offers simplicity of single-sample collection
- Identifies difficult-to-culture pathogens
- Yields a high level of sensitivity and specificity

Eurofins Diatherix Benefits:

TEM-PCR technology is a proprietary, multiplex amplification platform designed to overcome the challenges that exist with conventional laboratory methods.

Improved speed and accuracy of laboratory results lead to:

- Reduced antibiotic utilization
- Improved patient outcomes
- Cost reduction and avoidance
- Increased patient satisfaction
- Greater clinical value

Flu Plus Pathogens:

SARS-CoV-2 Influenza A A(H1N1)pdm09 Influenza B Respiratory Syncytial Virus (A & B) Human Rhinovirus/Enterovirus

A research letter recently published in JAMA (The Journal of the American Medical Association) found that rates of COVID-19 co-infections with other respiratory pathogens are 21%, higher than previously thought, suggesting that identification of another pathogen may not rule out the presence of the novel coronavirus.

Diatherix Eurofins SARS-CoV-2 virus has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories, and has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.



